Skip to main content
. 2019 Oct 17;20:375. doi: 10.1186/s12882-019-1574-9

Table 3.

Clinical characteristics of 11 cases of TAFRO syndrome with kidney biopsy

Case no./Ref. Age/sex UP Alb (g/dL) Cr (mg/dL) CRP (mg/dL) VEGF/IL-6 (pg/mL) 1st Therapy/ response 2nd Therapy/ response Kidney biopsy findings
Thrombi Endothelial swelling Endocapillary proliferation Mesangiolysis Mesangial proliferation Double contours of GBM Glomerular Ig deposition by IF Subendothelial lesions by EM Electron dense deposits Diagnosis by authors
1/ [4] 38 / M n.d. 3 2.59 11.18 4420 / n.d. PSL / good - n.d. n.d. n.d. n.d. Yes Yes Yes n.d. n.d. MPGN-like
2/ [5] 55 / F 0.54 (g/g・Cr) 2.7 2.1 4.1 464 / 11.7 Pulse steroid / good - n.d. n.d. n.d. n.d. Yes Yes Yes n.d. No MPGN-like
3/ [6] 76 / F 0.30 (g/day) 1.2 3.02 16 1350 / 49.2 PSL /good - n.d. n.d. Yes n.d. Yes Yes No Yes No MPGN-like
4/ [7] 79 / F 2.65 (g/g・Cr) 2.4 1.85 3.9 15.6 / 3.76 Pulse steroid, PE / bad RTX / good n.d. n.d. No Yes No Yes No Yes n.d. TMA-like
5/ [8] 70 / M 0.33 (g/day) 2.5 1.28 9.85 126 / 33 Pulse steroid / good - No Yes No Yes No Yes No Yes No MPGN-like
6/ [9] 61 / F n.d. 2.8 2.14 23.12 n.d. / 722.6 Pulse steroid, TCZ, RTX / good - n.d. Yes n.d. Yes Yes Yes No n.d. n.d. MPGN-like
7/ [10] 80 / F 0.41 (g/day) 2.8 1.17 7.3 454 / 21.6 PSL /bad TCZ / good No Yes Yes No No Yes Yes Yes No TMA-like
8/ [11] 51 / F 0.52 (g/g・Cr) 2.5 1.03 4.58 198 / 21.2 Pulse steroid / good - n.d. Yes No Yes No Yes No n.d. n.d. TMA-like
9/ [12] 84 / M 0.30 (g/day) 2.4 2.31 8.3 177 / 12.3 PSL, PE /bad TCZ / good No Yes Yes Yes No No No Yes No TMA-like
10/ [13] 54 / F 3.2 (g/g・Cr) 2.4 1.11 7 n.d. / 8.2 PSL /good - No Yes No No No No No Yes No Endothelial injury
our case 48 / F 1.57 (g/g・Cr) 2.6 1.32 18.33 494 / 166 Pulse steroid /bad TCZ / good No Yes Yes Yes No Yes No Yes No TMA-like

Abbreviations: Alb Albumin; Cr Creatinine, CRP C-reactive protein, EM Electron microscopy, GBM Glomerular basement membrane, IF Immunofluorescence, Ig Immunoglobulin, IL Interleukin, MPGN Membranoproliferative glomerulonephritis, n.d. not data, PE Plasma exchange, PSL Prednisolone, RTX rituximab, TCZ tocilizumab, TMA Thrombotic microangiopathy, UP Urinary protein, VEGF Vascular endothelial growth factor